Splenectomy for the treatment of hairy-cell leukemia.
Samuel Eldar, Kemeny Mm, Benfield
Abstract
Samuel Eldar, Kemeny Mm, Benfield
Abstract
In conclusion, patients with hairy-cell leukemia may need no therapy for prolonged periods. If they are symptomatic from hypersplenism, they may be expected to benefit from splenectomy. Some patients will have a relapse after splenectomy. At this time, there is no method to predict which patients will have a long term benefit from splenectomy, and we believe that operation should not be recommended as the primary therapy for hairy-cell leukemia.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In conclusion, patients with hairy-cell leukemia may need no therapy for prolonged periods. If they are symptomatic from hypersplenism, they may be expected to benefit from splenectomy. Some patients will have a relapse after splenectomy. At this time, there is no method to predict which patients will have a long term benefit from splenectomy, and we believe that operation should not be recommended as the primary therapy for hairy-cell leukemia.
Key concepts: Splenectomy, Medicine, Hairy cell leukemia, Leukemia, Hairy Cell, Surgery, Spleen, Immunology